The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series by Russi, Linda et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF
Therapy in Patients with Refractory Crohn’s Disease: A Case Series
Russi, Linda; Scharl, Michael; Rogler, Gerhard; Biedermann, Luc
DOI: https://doi.org/10.1159/000481400
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-145257
Journal Article
Published Version
Originally published at:
Russi, Linda; Scharl, Michael; Rogler, Gerhard; Biedermann, Luc (2017). The Efficacy and Safety of
Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn’s Disease:
A Case Series. Inflammatory Intestinal Diseases, 2(2):131-138.
DOI: https://doi.org/10.1159/000481400
E-Mail karger@karger.com
 Original Paper 
 Inflamm Intest Dis 2017;2:131–138 
 DOI: 10.1159/000481400 
 The Efficacy and Safety of Golimumab as 
Third- or Fourth-Line Anti-TNF Therapy in 
Patients with Refractory Crohn’s Disease: 
A Case Series 
 Linda Russi    Michael Scharl    Gerhard Rogler    Luc Biedermann 
 Department of Gastroenterology and Hepatology, University Hospital Zurich, and University of Zurich, 
 Zurich , Switzerland 
 
ministration.  Conclusions: A considerable fraction of this 
highly selected subgroup of difficult-to-treat CD patients re-
sponded to golimumab, indicating a promising potential for 
refractory CD patients, including those with multiple previ-
ous anti-TNF exposures.  © 2017 S. Karger AG, Basel 
 Introduction 
 Golimumab (Simponi ® , Janssen, Beerse, Belgium) is 
a fully human IgG1 monoclonal antibody, which inhibits 
tumor necrosis factor alpha (TNF-α)  [1] . It is 1 of 4 
TNF-α antagonists available for treating inflammatory 
bowel disease (IBD). The other agents approved for IBD 
in Switzerland are adalimumab, infliximab, and certoli-
zumab pegol. Golimumab is approved for the subcutane-
ous (s.c.) and intravenous treatment of rheumatoid ar-
thritis  [2–6] and s.c. treatment of ankylosing spondylitis 
 [7] , psoriatic arthritis  [8] , and ulcerative colitis  [6, 9, 10] . 
However, despite the well-established efficacy of the oth-
er 3 anti-TNF agents available for Crohn’s disease (CD), 
golimumab has not been explored for this indication. 
This may be due to a multitude of reasons, including stra-
tegical considerations by the manufacturer and regula-
tory issues/burden.
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 Abstract 
 Background: The TNF-α antagonist golimumab is approved 
for the treatment of ulcerative colitis but not for Crohn’s dis-
ease (CD). We herein report a case series of 8 difficult-to-treat 
patients with severe and refractory CD receiving golimumab 
as an off-label rescue medication and fourth-line anti-TNF 
agent in our tertiary referral inflammatory bowel disease 
center.  Methods: We performed a retrospective analysis of 
clinical, biochemical, and radiological as well as endoscopic 
parameters. The patients all suffered from severe refractory 
CD with ongoing symptoms. Moreover, all 8 patients had 
previously been treated with all 3 other TNF-α antagonists 
approved for CD in Switzerland (infliximab, adalimumab, 
and certolizumab pegol) without durable clinical response. 
 Results: Three out of 8 patients showed a primary nonre-
sponse. Among the 5 patients responding after induction, 1 
patient showed a loss of response, and in 1 patient, treat-
ment was terminated due to side effects. Three patients have 
a continuous clinical response under golimumab. We did not 
observe any severe adverse events during golimumab ad-
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 There are neither clinical trials nor case series on go-
limumab in CD available in the literature, except for a 
small retrospective series in 6 children from Finland, re-
porting modest beneficial effects  [11] . Despite substantial 
progress with a growing number of therapeutic agents in 
recent years and an impressively large pipeline of emerg-
ing treatment options  [12, 13] , many unmet needs and 
treatment gaps remain in CD  [14] . 
 Eight patients with severe CD from the IBD clinic at 
the University Hospital of Zurich received off-label go-
limumab after all other approved TNF-α antagonists, im-
munosuppressants, and experimental therapies within 
clinical trials had either turned out inefficient or had 
caused intolerable adverse effects. All patients were previ-
ous anti-TNF responders to at least 1 agent. Primary anti-
TNF nonresponders were not considered for off-label go-
limumab treatment. We herein report on our therapeutic 
experience with golimumab in CD in this case series, 
which is, to the best of our knowledge, the first published 
experience in adult CD patients.
 Materials and Methods 
 We retrospectively analyzed our patient database from the IBD 
clinic at the University Hospital of Zurich including all CD pa-
tients ever having received at least 1 dose of golimumab. We re-
viewed patients’ medical history regarding demographics, disease 
characteristics, course of the disease, treatment history as well as 
current medication, and clinical data regarding efficacy of golim-
umab (including adverse events, endoscopy, and imaging results 
whenever available). Our center features an electronic database 
with a standardized report form, including, amongst others, Har-
vey Bradshaw index, current and previous medication, extraintes-
tinal manifestations (EIMs), comorbidities, and adverse events. 
 Ethical Considerations 
 The off-label use of golimumab in our CD patients was indi-
vidually approved by the patients’ health insurances. Due to recent 
changes in the Swiss Law on Human Research (Humanforschungs-
gesetz), the patients signed a general consent to use their data for 
scientific purposes at the beginning of 2016, allowing retrospective 
data analysis.
 Results 
 All 8 patients suffered from refractory CD and had 
previously received 3 anti-TNF agents as well as several 
other approved and investigational drugs. In addition, all 
patients suffered from an extensive bowel involvement 
and the majority also from EIMs, especially on the joints 
and skin. Likewise, a stricturing and penetrating disease 
behavior occurred in most cases. The patients showed a 
variable response to previous treatments, with either pri-
mary nonresponse or loss of response as well as side ef-
fects requiring drug cessation. Several patients had previ-
ously undergone surgery (some repetitively), including 
ileocecal resection and perianal fistulae surgery, abscesses 
drainage, and even colectomy. In the following, a brief 
description of each individual case is provided.
 Case 1 
 A 44-year-old man, who was a former smoker with a 
long history of spondyloarthropathy, had been suffering 
from steroid-refractory CD for 18 years (Montreal clas-
sification: A1, L3, B3;  Table 1 ). CD was localized in the 
terminal ileum, colon, and rectum. He also suffered from 
recurrent perianal fistulae requiring surgery. The list of 
previous treatments included 5ASA (mesalamine), ste-
roids, infliximab (which was initially successful but later 
induced an allergic reaction), and subsequently adalim-
umab, which was ineffective. He did not tolerate azathio-
prine (arthralgia, nausea). Subsequently, certolizumab 
combined with methotrexate was administered. After di-
agnosis of liver fibrosis, methotrexate was stopped. Short-
ly after withdrawal of methotrexate, a loss of response to 
certolizumab pegol therapy occurred. Golimumab com-
bined with 6-mercaptopurine was started. After initial 
clinical improvement, the interval of golimumab injec-
tion had to be shortened due to an increase in clinical 
symptoms. In addition, the patient repeatedly suffered 
from a  Clostridium difficile infection, further impairing 
his clinical condition. However, overall, the patient’s con-
dition during treatment with golimumab considerably 
improved (notable clinical response but not remission), 
oral steroids could be tapered (from 10 mg to 2.5 mg 
prednisone per day), and biochemical improvement was 
observed in parallel ( Table 2 ). The patient is currently still 
under golimumab treatment with mild disease symp-
toms. 
 Case 2 
 A 46-year-old nonsmoking man with a 24-year history 
of steroid-dependent CD without EIMs suffered mainly 
from involvement of the ileum (Montreal classification: 
A1, L3, B3). During the disease course, he developed 2 
ileal strictures requiring surgery. Two blind-ending fistu-
lae originating from the terminal ileum were seen on 
magnetic resonance imaging (MRI). He had been treated 
with mesalazine and azathioprine, without success, and 
with certolizumab, with initial treatment response but a 
rapid loss of response. Next, infliximab treatment was 
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 Table 2. Endoscopy, imaging, and laboratory findings (when available)
Case Prior to golimumab treatment During golimumab treatment After golimumab treatment
a Endoscopy, imaging
1 Colo: left-sided colitis  
2 MRI: progressive affection of the distal and 
terminal ileum with a light prestenotic dilatation, 
enlarged mesenterial lymph nodes; Colo: distinct 
ileitis, stenosis (probably due to inflammatory 
edema), solitary aphthous ulcerations in the 
descending colon
MRI: constant result, except no prestenotic 
dilatation and 2 fistulae from the terminal 
ileum to the mesenterial adipose tissue
3 Rectosigmoidoscopy: active colitis and proctitis; 
Sono: active colitis
Sono: suspected active colitis especially in 
the colon transversum; Colo: CD without 
active inflammation
4 MRI: focal colitis in the descending colon with 
perifocal abscess formation, complex perianal 
system of fistulae; CT: new fistulae
Colo: persisting pancolitis, perianal 
nonirritated fistula
 
5 Colo: stenosis of the anastomosis, light ileitis, 
edematous colon; MRI: inflammatory reaction in 
the neoterminal ileum, progressive reactive 
lymphadenopathy
MRI and Colo: constant result; capsule 
endoscopy: multiple ulcerations in the distal 
ileum; rectosigmoidoscopy: distal proctitis, 
light ulcerations
MRI: constant result; Colo: constant result, 
except slightly ulcerative pancolitis
6 Colo: inflammatory altered ileocecal valve; MRI: 
long fibrostenosis in the ileum; Sono: long severe 
ileitis; Sono: after the operation slightly prominent 
ileum
Sono: constant result; Sono: light wall 
thickening in the neoterminal ileum
 
7 Colo: severe pancolitis with ulcerations and 
pseudopolyps, increased friability; Colo: after the 
ileocecal resection, severe colitis, possible fistula, 
light stenosis; MRI: disappeared haustration, short 
fistula between the distal jejunum/proximal ileum 
and the descending colon
Colo: severe inflammatory activity in the 
colon and the neoterminal ileum, stenosis 
and fistula
MRI: fistula from the sigmoid colon through 
the musculus rectus to the subcutaneous 
adipose tissue; Colo: fistula from the distal 
sigmoid colon to the bladder, enterosigmoid 
fistula, highly active colitis
8 MRI: wall thickening of the terminal ileum and the 
colon, abdominal lymphadenopathy
Sono: distinct colitis transversum and 
ascendens, wall thickening in the terminal 
ileum; Colo: inflammatory alterations in the 
terminal ileum, the colon ascendens and 
transversum, stenotic and inflammatory 
altered valve
b Laboratory findings
1 CRP: 13, Lc: 12.75, Thromb: 345, Hb: 113, 
calprotectin: 1330
CRP: 8.1, Lc: 5.28, Thromb: 129, Hb: 147, 
calprotectin: 1,037
2 CRP: 19, Lc: 5.83, Thromb: 370, Hb: 131, 
calprotectin: 1,855
CRP: 3.5, Lc: 17.35, Thromb: 346, Hb: 90, 
calprotectin: 189
CRP: <0.3, Lc: 6.67, Thromb: 227, Hb: 146, 
calprotectin: <30
3 CRP: 11, Lc: 12.71, Thromb: 424, Hb: 154, 
calprotectin: 932
CRP: 1.1, Lc: 8.18, Thromb: 376, Hb: 164, 
calprotectin: 405
4 CRP: 5.6, Lc: 8.45, Thromb: 406, Hb: 134, 
calprotectin: 242
CRP: 1.4, Lc: 8.84, Thromb: 241, Hb: 159
5 CRP: 2.4, Lc: 10.88, Thromb: 380, Hb: 130, 
calprotectin: 113
CRP: 2.2, Lc: 13.17, Thromb: 360, Hb: 126, 
calprotectin: 171
CRP: 4.1, Lc: 9.06, Thromb: 388, Hb: 107
6 CRP: 21, Lc: 7.65, Thromb: 285, Hb: 125, 
calprotectin: 1,387
CRP: 2.6, Lc: 8.19, Thromb: 229, Hb: 146, 
calprotectin: 290
 
7 CRP: 22, Lc: 6.51, Thromb: 531, Hb: 80, 
calprotectin: 5,489
CRP: 31, Lc: 6.57, Thromb: 498, Hb: 94, 
calprotectin: 428
8 Calprotectin: 1,343 CRP: 88, Lc: 11.09, Thromb: 379, Hb: 120
Colo, colonoscopy; MRI, magnetic resonance imaging; Sono, sonography; CT, computed tomography; CD, Crohn’s disease; CRP, C-reactive protein; 
Lc, leucocytes; Thromb, thrombocytes; Hb, hemoglobin.
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initiated, which was clinically effective but had to be 
stopped due to an infusion reaction. Subsequently, the 
patient received adalimumab associated with a primary 
nonresponse and then participated in a multi-center 
phase II trial with an anti-IL-6 antibody. Finally, the pa-
tient received golimumab for 7 months. Due to a poten-
tial fibrostenotic ileal involvement, the patient again 
showed a primary nonresponse, and the decision for lap-
aroscopic-assisted ileocecal resection with a segmental il-
eal resection and a strictureplasty of the proximal ileum 
was made. During golimumab treatment, neither clinical 
symptoms nor laboratory and MRI findings did improve . 
 Case 3 
 A 35-year-old nonsmoking man had been suffering 
from a steroid-dependent CD (Montreal classification: 
A1, L3, B3) with several EIMs, including involvement of 
the eyes and the joints, for 10 years. He also had Cogan 
syndrome with deafness as a result of a bilateral cochleo-
vestibular disorder  [15, 16] . The upper gastrointestinal 
tract and the entire colon and rectum were affected. Sev-
eral perineal abscesses and a perianal fistula required sur-
gical treatment. Initially, he was treated with azathioprine 
with primary nonresponse. Thereafter, he consecutively 
received infliximab, certolizumab, and adalimumab, all 
with a rapid loss of response or nonresponse as well as 
with an infliximab-induced hepatitis. Methotrexate was 
not tolerated due to nausea and impairment of taste. 
Treatment with cyclosporine had to be stopped due to 
neurotoxicity and insufficient response. Subsequently, 
golimumab was started with an initially limited response 
to the 50-mg dosing every 4 weeks. In this situation, the 
dose was increased to 100 mg, and the administration in-
terval was shortened to 2 weeks. The patient initially 
showed a prolonged clinical response with clinical and 
laboratory improvement .  However, steroids could not be 
permanently reduced below 20 mg of prednisone per day, 
and no evident improvement on ultrasound and endo-
scopic findings could be observed. During ongoing treat-
ment with golimumab of 4 years, the patient had to un-
dergo surgical treatment of perineal abscesses twice. Due 
to lack of success in tapering systemic steroids, moderate 
residual endoscopic inflammatory activity, as well as clin-
ical symptoms, we considered this case as loss of response 
to golimumab despite undoubtable overall temporary 
clinical benefit.
 Case 4 
 A 51-year-old smoking man (45 pack-years) with a 21-
year history of steroid-dependent CD (Montreal classifi-
cation: A1, L2, B2) developed several abscesses, fistulae, 
and stenosis. Initially, he was treated with steroids and 
then azathioprine, which caused a pancreatitis. Inflix-
imab, adalimumab, and certolizumab were administered 
subsequently with primary response to all 3 agents, how-
ever, followed by loss of response to all TNF inhibitors. 
Thereafter, the patient participated in a phase II trial with 
a s.c. anti-integrin antibody with primary nonresponse 
and early treatment withdrawal after entering the early 
open-label phase. Due to severe active inflammatory in-
volvement of the descending colon and sigma, a retro-
peritoneal abscess formation, and development of an en-
terocutaneous fistula, segment resection of the left hemi-
colon was performed. After surgery, golimumab was 
initiated as there was residual inflammation in the re-
maining left colon proximal and distal to the anastomo-
sis. Seven months after the colonic resection, the ileos-
tomy was reversed. Seven months after the initiation of 
golimumab, mild-to-moderate diarrhea reappeared at 
the end of the 4-week golimumab interval, and the fistula 
was clinically reactivated. Therefore, treatment with goli-
mumab was continued in a combination with methotrex-
ate (15 mg s.c. once per week) despite a lack of supporting 
data for methotrexate/golimumab combination treat-
ment in CD, with consecutive absence of clinical symp-
toms at the end of the 4-week interval. The patient cur-
rently is in clinical remission and is still under golimu-
mab in combination with methotrexate for more than 1 
year.
 Case 5 
 A 44-year-old woman was diagnosed with CD 14 years 
ago and developed a steroid-refractory disease course 
(Montreal classification: A1, L3, B3). She was a smoker 
and had an affection of the terminal ileum, where she also 
had a stenosis. In addition, she suffered from enteropath-
ic ankylosing spondylitis. The patient underwent ileoce-
cal resection twice within 9 years and had repeated di-
latations of the anastomosis. She had sequentially been 
treated with azathioprine, methotrexate, budesonide, ve-
dolizumab, infliximab, adalimumab, certolizumab, to-
cilizumab (an already available antibody directed against 
IL-6, approved for rheumatoid arthritis), cyclosporine, 
and tacrolimus, all with primary nonresponse, except for 
infliximab (loss of response after initial good response). 
A re-exposure to infliximab had to be stopped due to a 
psoriasiform exanthema, insufficient through level, and 
antibodies to infliximab. Thus, golimumab was started in 
combination with azathioprine. Steroids could be com-
pletely withdrawn. However, no biochemical or endo-
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scopic improvement was observed. In view of the residu-
al clinical symptoms, the patient was considered as a pri-
mary nonresponder, and golimumab was stopped.
 Case 6 
 A 36-year-old smoking man had been suffering from 
steroid-refractory CD for 17 years (Montreal classifica-
tion: A2, L3, B2) with enteropathic spondyloarthropathy. 
In the terminal ileum, he had a long fibrostenotic lesion. 
He had been treated with infliximab and adalimumab (in-
termittently in combination with methotrexate) with pri-
mary nonresponse. The patient had received certolizum-
ab with a positive effect on his rheumatologic symptoms. 
An ileocecal resection was performed, certolizumab was 
stopped, and golimumab was started, resulting in clinical 
remission. The back pain and the laboratory findings 
consecutively improved.
 Case 7 
 A 28-year-old nonsmoking woman had been suffering 
from steroid-dependent CD (Montreal classification: A2, 
L2, B3) for 10 years. She had disease activity in the ileum, 
colon, and rectum and developed several fistulae, steno-
sis, and an erythema nodosum. Besides, she repeatedly 
needed blood transfusions because of recurring anemia 
as a result of chronic inflammation, blood loss, and iron 
as well as vitamin B 12 deficiency. She had been treated 
with azathioprine and, thereafter, with infliximab, which 
was stopped because of worsening of symptoms. After il-
eocecal resection, the patient again received infliximab, 
which caused a severe allergic reaction with exanthema 
and bronchospasm. Subsequently, certolizumab and 
adalimumab were administered, both inducing clinical 
response, but a loss of response after 2 and 6 months, re-
spectively, occurred. Ustekinumab was given with a 270-
mg s.c. induction dose followed by 90 mg every 8 weeks 
s.c. Due to an insufficient clinical response to ustekinu-
mab, golimumab was started. There was no clinical ben-
efit and no endoscopic improvement. A decision for total 
colectomy with ileostomy and resection of the fistulae 
was made, and significant clinical improvement after the 
surgical intervention occurred.
 Case 8 
 A 30-year-old smoking woman had been suffering 
from steroid-dependent CD for 10 years (Montreal clas-
sification: A1, L3, B3). She had several EIMs (erythema 
nodosum/pyoderma gangrenosum, episcleritis/keratitis, 
and arthritis). The terminal ileum and the colon were af-
fected. The medical treatment consisted initially of aza-
thioprine. Afterwards, infliximab was given, which had to 
be withdrawn due to exanthema and loss of response. 
Certolizumab had to be stopped due to a severe psoriasi-
form skin reaction. Next, treatment with adalimumab 
had to be withdrawn due to a rapid loss of response. Go-
limumab was given, inducing clinical response. However, 
due to the appearance of oro-facio-genital pustules, go-
limumab was also stopped. The patient was subsequently 
included into clinical trials and has still active disease at 
present.
 Discussion 
 In our case series, we report on the clinical potential of 
golimumab in adult CD patients, involving a highly selec-
tive population of tertiary referral centers’ difficult-to-
treat, refractory, and treatment-exposed patients. The fi-
nal outcome of our 8 patients was primary nonresponse 
in 3 cases, loss of response in 1 case, cessation due to side 
effects in 1 case, and ongoing clinical response in 3 pa-
tients. We did not observe severe adverse events associ-
ated with golimumab, with the exception of severe pso-
riasiform pustulosis. This side effect is a well-known 
complication of anti-TNF treatment.
 Evidently, in each patient in this series, the odds of re-
sponse prior to initiation were not in favor of golimumab, 
as all patients aggregated at least 1 but mostly several risk 
factors for primary nonresponse or loss of response, i.e., 
long disease duration; previous treatment failure to all 
other TNF-inhibiting agents available for CD in Switzer-
land as well as a multitude of established and investiga-
tional agents; preexisting severe and extensive intestinal 
alterations; previously experienced side effects to anti-
TNF and other agents; and active smoking.
 Therefore, considering the overall baseline character-
istics and the difficult-to-treat patient profile of our small 
cohort, the overall clinical results of golimumab are note-
worthy. In most European countries, there are 3 TNF-α 
antagonists available and approved for ulcerative colitis 
but only 2 for CD. With the new treatment options on the 
horizon, such as vedolizumab, ustekinumab, mongersen, 
and Janus kinase inhibitors, the availability of a third or 
fourth anti-TNF agent for refractory CD may be less of an 
issue in the future. However, for all of these compounds, 
considerable gaps in efficacy, such as steroid-free clinical 
remission or mucosal healing, have been reported. In ad-
dition, none of these agents have been tested against anti-
TNF agents. Thus, it remains unclear whether these 
emerging treatment options are superior to anti-TNF 
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agents. Allez et al.  [17] , several years ago, showed that 
there is a place for a third anti-TNF agent, even after 2 
prior anti-TNF antibodies had failed. Accordingly, and 
one step further, this small case series suggests that even 
a fourth anti-TNF-inhibiting agent may have some clini-
cal potential in refractory CD patients with prior triple 
anti-TNF agent failure. In addition, golimumab has the 
advantage of a well-known safety profile  [9, 10] . For off-
label use in CD in Switzerland, a specific agreement with 
the health insurance company, the manufacturer, or a 
combination of both is necessary. Treatment costs are in 
a comparable range with other biologics in the field of 
IBD. Thus, we believe that golimumab apparently may 
represent a yet underused rescue treatment option in CD.
 As with any case series, our report has several limita-
tions, including the difficulty to compare patients with a 
nonstandardized follow-up, retrospective analysis, and 
single-center design. Furthermore, we report on an insuf-
ficient number of patients for robust calculation of re-
sponse and remission values, and there is a lack of com-
parison to clinical trial data of other agents. However, if a 
bias would have to be expected in terms of efficacy, rath-
er an underestimation of the clinical effect might have 
occurred in this highly selected fraction of refractory and 
highly treatment-exposed CD patients. Ideally, a pro-
spective double-blind randomized clinical trial of golim-
umab in CD would provide robust data on its efficacy. 
However, in view of strategic considerations of the man-
ufacturer, such a trial most likely will not be performed. 
 In conclusion, golimumab has a clinical potential and 
is safe in severe refractory and highly treatment-exposed 
CD patients, even after multiple prior anti-TNF agent ex-
posures and failure of treatment.
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